<DOC>
	<DOCNO>NCT03077750</DOCNO>
	<brief_summary>A Multicenter , Randomized , Double-Blind , Vehicle-Controlled Phase II Study Evaluate Efficacy , Tolerability , Safety Topical VBP-245 Pediatric Subjects Treatment Molluscum Contagiosum ( VBP-245-MCV ) .</brief_summary>
	<brief_title>A Study VBP-245 Pediatric Patients With Molluscum Contagiosum</brief_title>
	<detailed_description />
	<mesh_term>Molluscum Contagiosum</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion : 1 . Males female age 218 year screen ; 2 . MC diagnose general physician , dermatologist pediatrician refers treatable topical agent ; 3 . Individuals least 1 , exceed 15 molluscum select designated treatment area : 4 . Individuals whose treatment area locate anywhere body except follow prohibited area include : eye area ( include eyelid ) , lip , mouth cavity , nasal cavity , inner ear , palm hand , sol foot anogenital area ; 5 . Free systemic dermatologic disorder , opinion investigator , interfere study result increase risk adverse advent ; 6 . Free atopic dermatitis treatment area , opinion investigator , potentially get inflamed irritated course treatment ; 7 . Parent guardian able give appropriate inform consent determine approve institutional review board ( IRB ) ; 8 . Individuals generally good health determine investigator ; 9 . Willingness ability parent guardian read , understand , sign IRBapproved inform consent form nature study fully explain question answer ; 10 . Individuals willing start new product OTC prescription treatment discontinue treatment investigator feel may interfere evaluation test product ; 11 . Individuals willing avoid use cosmetic product , cream , salve , ointment treatment area ( ) ; 12 . Individuals willing able thoroughly follow product use instruction , attend schedule visit successfully complete study ; 13 . Individuals willing able begin office base treatment duration study ; 14 . Female subject childbearing age negative pregnancy test enrolment time study ; 15 . Female subject breastfeed enrolment time study ; 16 . Female subject intend become pregnant participation study ; 17 . Female subject reproductive potential must agree practice medically acceptable form birth control study â€¢ Medically acceptable form birth control may use subject and/or his/her partner include : Established use hormonal method contraception ( oral , injected , implanted , patch vaginal ring ) Barrier method contraception spermicide : condom occlusive cap ( diaphragm cervical/Vault cap ) spermicidal foam/gel/film/cream suppository ; Intrauterine divide ( IUD ) intrauterine system ( IUS ) ; Surgical sterilization ( vasectomy , tubal occlusion , bilateral salpingectomy ) ; Abstinence heterosexual intercourse ; line prefer usual lifestyle subject . Periodic abstinence ( calendar , ovulation , symptothermal , post ovulation method ) withdrawal NOT acceptable method contraception Subjects meet follow exclusion criterion exclude study : 1 . Mentally incompetent unable willing give write informed consent via parent guardian meet study requirement 2 . Known history hypersensitivity topical povidoneiodine 3 . Significant atopic dermatitis surround molluscum contagiosum lesion judge investigator 4 . Individual lesion great 5mm diameter 5 . Pregnant , breastfeed unwilling undergo acceptable form contraception duration study ; 6 . Molluscum lesion locate eye area ( include eyelid ) , lip , mouth cavity , nasal cavity , inner ear , palm hand , sol foot anogenital area ; 7 . Have participate investigational trial within 30 day prior enrollment ; 8 . Have require require systemic intake immunosuppressive immunomodulatory medication ( include oral parenteral corticosteroid ) within 30 day prior enrollment course study . 9 . Have uncontrolled current infection ; 10 . Female subject pregnant , lactate plan become pregnant , breastfeed ; 11 . Have chronic acute medical condition , opinion investigator , may interfere study result place subject undue risk ( immunodeficiency relevant genetic syndrome ) ; 12 . Have active malignancy undergo treatment malignancy nonmelanoma skin cancer ; Subjects view Principal Investigator able complete study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>viral skin disease</keyword>
</DOC>